Consistently verified and quantified by PSA enhancer-promoter luciferase reporter assays, this PKC-mediated inhibition of AR activity is consistent with the aforementioned mechanisms describing the nuclear exclusion of AR in prostate cancer cells secondary to melatonin treatment. This evidence concerns the gene PRRT2 and prostate carcinoma.